Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing novel therapeutic solutions. The company strives to identify, develop, and commercialize treatments that address significant unmet medical needs across various therapeutic areas, including disorders of the central nervous system, respiratory conditions, cardiovascular issues, metabolic syndromes, and inflammatory diseases. Its primary investigational drug, RP5063, is currently undergoing Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I studies exploring its potential in a broad range of other conditions, such as bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic manifestations associated with dementia or Alzheimer's, Parkinson's disease-related psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Additionally, Reviva is developing RP1208, a preclinical candidate targeting both depression and obesity. The company's operations are based in Cupertino, California.
